» Articles » PMID: 33917404

Biomaterials for Drugs Nose-Brain Transport: A New Therapeutic Approach for Neurological Diseases

Overview
Publisher MDPI
Date 2021 Apr 30
PMID 33917404
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

In the last years, neurological diseases have resulted in a global health issue, representing the first cause of disability worldwide. Current therapeutic approaches against neurological disorders include oral, topical, or intravenous administration of drugs and more invasive techniques such as surgery and brain implants. Unfortunately, at present, there are no fully effective treatments against neurodegenerative diseases, because they are not associated with a regeneration of the neural tissue but rather act on slowing the neurodegenerative process. The main limitation of central nervous system therapeutics is related to their delivery to the nervous system in therapeutic quantities due to the presence of the blood-brain barrier. In this regard, recently, the intranasal route has emerged as a promising administration site for central nervous system therapeutics since it provides a direct connection to the central nervous system, avoiding the passage through the blood-brain barrier, consequently increasing drug cerebral bioavailability. This review provides an overview of the nose-to-brain route: first, we summarize the anatomy of this route, focusing on the neural mechanisms responsible for the delivery of central nervous system therapeutics to the brain, and then we discuss the recent advances made on the design of intranasal drug delivery systems of central nervous system therapeutics to the brain, focusing in particular on stimuli-responsive hydrogels.

Citing Articles

Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.

Ciftci F, Ozarslan A, Kantarci I, Yelkenci A, Tavukcuoglu O, Ghorbanpour M Pharmaceutics. 2025; 17(1).

PMID: 39861768 PMC: 11769154. DOI: 10.3390/pharmaceutics17010121.


Serum Albumin in Nasal Drug Delivery Systems: Exploring the Role and Application.

Mardikasari S, Katona G, Csoka I Pharmaceutics. 2024; 16(10).

PMID: 39458651 PMC: 11510880. DOI: 10.3390/pharmaceutics16101322.


Application of stimuli-responsive hydrogel in brain disease treatment.

Xie B, Xie H Front Bioeng Biotechnol. 2024; 12:1450267.

PMID: 39091971 PMC: 11291207. DOI: 10.3389/fbioe.2024.1450267.


Using Rapid Prototyping to Develop a Cell-Based Platform with Electrical Impedance Sensor Membranes for In Vitro RPMI2650 Nasal Nanotoxicology Monitoring.

Vasconez Martinez M, Reihs E, Stuetz H, Hafner A, Brandauer K, Selinger F Biosensors (Basel). 2024; 14(2).

PMID: 38392026 PMC: 10886737. DOI: 10.3390/bios14020107.


Bi-directional nasal drug delivery systems: A scoping review of nasal particle deposition patterns and clinical application.

Liu Y, Wu D Laryngoscope Investig Otolaryngol. 2023; 8(6):1484-1499.

PMID: 38130248 PMC: 10731484. DOI: 10.1002/lio2.1190.


References
1.
Hallschmid M . Intranasal Insulin for Alzheimer's Disease. CNS Drugs. 2021; 35(1):21-37. PMC: 7873098. DOI: 10.1007/s40263-020-00781-x. View

2.
Son I, Park Y, Lee S, Yang H, Moon H . Neuroprotective activity of triterpenoid saponins from Platycodi radix against glutamate-induced toxicity in primary cultured rat cortical cells. Molecules. 2007; 12(5):1147-52. PMC: 6149477. DOI: 10.3390/12051147. View

3.
Wang Q, Zuo Z, Cheung C, Leung S . Updates on thermosensitive hydrogel for nasal, ocular and cutaneous delivery. Int J Pharm. 2019; 559:86-101. DOI: 10.1016/j.ijpharm.2019.01.030. View

4.
Kuriakose D, Xiao Z . Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020; 21(20). PMC: 7589849. DOI: 10.3390/ijms21207609. View

5.
Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc L . Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012; 134(3):366-79. DOI: 10.1016/j.pharmthera.2012.03.003. View